Literature DB >> 10123837

Cost-effectiveness issues for home i.v. therapy in the United States.

R Allen1.   

Abstract

The popularity of home infusion therapy is increasing as it becomes recognized as a cost-effective alternative to hospitalization with the added benefit of improving patient quality of life. Selection of appropriate candidates for home i.v. therapy requires consideration of many variables pertaining to the medical and psychosocial suitability of the patient. Innovations in drug delivery devices have created opportunities for patients to receive parenteral therapy at home who would otherwise be considered inappropriate candidates for this treatment option. The cost of providing home IV therapy is mainly attributable to pharmacy and nursing services. Other contributing cost factors include the expense of ancillary supplies, supply delivery and management, and those costs created by administrative and regulatory requirements. When appropriately managed, home administration of IV medications can be a cost-effective way of delivering safe, effective, and quality care to an increasing population of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 10123837

Source DB:  PubMed          Journal:  Hosp Formul        ISSN: 0098-6909


  4 in total

1.  Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective.

Authors:  A O Wai; L Frighetto; C A Marra; E Chan; P J Jewesson
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 2.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 3.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 4.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.